Chemotherapy-induced neutropenia and the prognosis of colorectal cancer: a meta-analysis of cohort studies

References

• Liu R, Huang M, Zhao X, et al. Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen. Oncotarget. 2015 Nov 17;6(36):39018–39027. PubMed PMID: 26528696; PubMed Central PMCID: PMC4770753. DOI:10.18632/oncotarget.5730
   PubMed Web of Science ®Google Scholar
• Wang SL, Lee JJ, Liao AT. Chemotherapy-induced neutropenia is associated with prolonged remission duration and survival time in canine lymphoma. Vet J. 2015 Jul;205(1):69–73. PubMed PMID: 26004824. DOI:10.1016/j.tvjl.2015.04.032.
   PubMed Web of Science ®Google Scholar
• Tewari KS, Java JJ, Gatcliffe TA, et al. Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group. Gynecol Oncol. 2014 Jun;133(3):439–445. PubMed PMID: 24657300. DOI:10.1016/j.ygyno.2014.03.013
   PubMed Web of Science ®Google Scholar
• Abraham JE, Hiller L, Dorling L, et al. A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities. BMC Med. 2015;13:306. PubMed PMID: 26715442; PubMed Central PMCID: PMC4693418. DOI:10.1186/s12916-015-0547-5
   PubMed Web of Science ®Google Scholar
• Di Maio M, Gridelli C, Gallo C, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. The Lancet Oncology. 2005 9;6(9):669–677. DOI:10.1016/S1470-2045(05)70255-2.
   PubMed Web of Science ®Google Scholar
• Shitara K, Matsuo K, Oze I, et al. Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. Cancer Chemother Pharmacol. 2011 Aug;68(2):301–307. PubMed PMID: 20960191.
   PubMed Web of Science ®Google Scholar
• Gurney H. How to calculate the dose of chemotherapy. Br J Cancer. 2002 Apr 22;86(8):1297–1302. PubMed PMID: 11953888; PubMed Central PMCID: PMC2375356. Doi:10.1038/sj.bjc.6600139
   PubMed Web of Science ®Google Scholar
• Smoragiewicz M, Javaheri KR, Yin Y, et al. Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer. J Gastrointest Cancer. 2014 Dec;45(4):460–465. PubMed PMID: 25012517; eng.
   PubMedGoogle Scholar
• Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama. 2000 Apr 19;283(15):2008–2012. PubMed PMID: 10789670.
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010 Sep;25(9):603–605. PubMed PMID: 20652370. DOI:10.1007/s10654-010-9491-z.
   PubMed Web of Science ®Google Scholar
• Wang X, Yang HH, Liu Y, et al. Lycopene consumption and risk of colorectal cancer: a meta-analysis of observational studies. Nutrition and Cancer. 2016 Oct;68(7):1083–1096. PubMed PMID: 27472298. DOI:10.1080/01635581.2016.1206579
   PubMed Web of Science ®Google Scholar
• Shitara K, Matsuo K, Takahari D, et al. Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. Eur J Cancer. 2009 Jul;45(10):1757–1763. PubMed PMID: 19217278; eng.
   PubMed Web of Science ®Google Scholar
• Innominato PF, Giacchetti S, Moreau T, et al. Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). Chronobiology International. 2011; [cited. 586–600. Randomized Controlled Trial; Research Support, Non-U.S. Gov’t. available at http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/376/CN-00806376/frame.html PubMed Central; PMCID: PMCPubmed 21859417. doi:10.3109/07420528.2011.597532.
   PubMed Web of Science ®Google Scholar
• Rambach L, Bertaut A, Vincent J, et al. Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients. World J Gastroenterol. 2014 Feb 14;20(6):1565–1573. PubMed PMID: 24587632; PubMed Central PMCID: PMCPMC3925865. eng. DOI:10.3748/wjg.v20.i6.1565
   PubMed Web of Science ®Google Scholar
• Soveri LM, Hermunen K, De Gramont A, et al. Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: is efficacy an impact of toxicity? Eur J Cancer. 2014;50(17):2966–2974.
   PubMed Web of Science ®Google Scholar
• Sunaga T, Suzuki S, Kogo M, et al. The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy. Eur J Cancer Care (Engl). 2014 May;23(3):394–400. PubMed PMID: 24033646; eng.
   PubMed Web of Science ®Google Scholar
• Kotani D, Pashtoon K, Cecchini M, et al. Association between chemotherapy-induced neutropenia at 1-month and overall survival in patients receiving TAS-102 for metastatic colorectal cancer. Annals of Oncology. 2016;27:ii105.10.1093/annonc/mdw200.10.
   Web of Science ®Google Scholar
• Chen Y, Wang YR, Shi Y, et al. Timing of chemotherapy-induced neutropenia predicts prognosis in metastatic colon cancer patients: a retrospective study in mFOLFOX6 -treated patients. BMC Cancer. 2017;17(1). DOI:10.1186/s12885-017-3240-6.
   Web of Science ®Google Scholar
• Kim YH, Chung HH, Kim JW, et al. Prognostic significance of neutropenia during adjuvant concurrent chemoradiotherapy in early cervical cancer. J Gynecol Oncol. 2009 Sep;20(3):146–150. PubMed PMID: 19809547; PubMed Central PMCID: PMC2757558. DOI:10.3802/jgo.2009.20.3.146
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004 Jun 3;350(23):2343–2351. PubMed PMID: 15175436. DOI:10.1056/NEJMoa032709
   PubMed Web of Science ®Google Scholar
• Kuebler JP, Wieand HS, O’Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007 Jun 1;25(16):2198–2204. PubMed PMID: 17470851. DOI:10.1200/JCO.2006.08.2974
   PubMed Web of Science ®Google Scholar
• Gamelin E, Delva R, Jacob J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol. 2008 May 1;26(13):2099–2105. PubMed PMID: 18445839. DOI:10.1200/JCO.2007.13.3934
   PubMed Web of Science ®Google Scholar
• Capitain O, Asevoaia A, Boisdron-Celle M, et al. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. Clin Colorectal Cancer. 2012 Dec;11(4):263–267. PubMed PMID: 22683364. DOI:10.1016/j.clcc.2012.05.004
   PubMed Web of Science ®Google Scholar
• Kaldate RR, Haregewoin A, Grier CE, et al. Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. Oncologist. 2012;17(3):296–302. PubMed PMID: 22382460; PubMed Central PMCID: PMC3316912. DOI:10.1634/theoncologist.2011-0357
   PubMed Web of Science ®Google Scholar
• Gurney HP, Ackland S, Gebski V, et al. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol. 1998 Jul;16(7):2299–2304. PubMed PMID: 9667243.
   PubMed Web of Science ®Google Scholar
• Ratain MJ. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol. 1998 Jul;16(7):2297–2298. PubMed PMID: 9667242.
   PubMed Web of Science ®Google Scholar
• Delord JP, Umlil A, Guimbaud R, et al. Population pharmacokinetics of oxaliplatin. Cancer Chemother Pharmacol. 2003 Feb;51(2):127–131. PubMed PMID: 12647013. DOI:10.1007/s00280-002-0550-3
   PubMed Web of Science ®Google Scholar
• Lyman GH, Sparreboom A. Chemotherapy dosing in overweight and obese patients with cancer. Nat Rev Clin Oncol. 2013 Aug;10(8):451–459. PubMed PMID: 23856744. DOI:10.1038/nrclinonc.2013.108.
   PubMed Web of Science ®Google Scholar
• Schwenkglenks M, Jackisch C, Constenla M, et al. Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Support Care Cancer. 2006 Sep;14(9):901–909. PubMed PMID: 16622653. DOI:10.1007/s00520-006-0034-9
   PubMed Web of Science ®Google Scholar
• Abraham JE, Guo Q, Dorling L, et al. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Clin Cancer Res. 2014 May 1;20(9):2466–2475. PubMed PMID: 24599932. DOI:10.1158/1078-0432.CCR-13-3232
   PubMed Web of Science ®Google Scholar
• Kislukhin G, Murphy ML, Jafari M, et al. Chemotherapy-induced toxicity is highly heritable in Drosophila melanogaster. Pharmacogenet Genomics. 2012 Apr;22(4):285–289. PubMed PMID: 22336958; PubMed Central PMCID: PMC3303944. DOI:10.1097/FPC.0b013e3283514395
   PubMed Web of Science ®Google Scholar
• Cirulli ET, Goldstein DB. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet. 2010 Jun;11(6):415–425. PubMed PMID: 20479773. DOI:10.1038/nrg2779.
   PubMed Web of Science ®Google Scholar
• Okazaki T, Javle M, Tanaka M, et al. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res. 2010 Jan 1;16(1):320–329. PubMed PMID: 20028759; PubMed Central PMCID: PMC2802655. DOI:10.1158/1078-0432.CCR-09-1555
   PubMed Web of Science ®Google Scholar
• Maione P, Rossi A, Di Maio M, et al. Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer? Lung Cancer. 2009 Oct;66(1):8–14. PubMed PMID: 19328587. DOI:10.1016/j.lungcan.2009.02.022
   PubMed Web of Science ®Google Scholar
• Mandrekar SJ, Schild SE, Hillman SL, et al. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer. 2006 Aug 15;107(4):781–792. PubMed PMID: 16847887. DOI:10.1002/cncr.22049
   PubMed Web of Science ®Google Scholar
• Kohne CH, Cunningham D, Di Costanzo F, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002 Feb;13(2):308–317. PubMed PMID: 11886010.
   PubMed Web of Science ®Google Scholar
• Kowanetz M, Wu X, Lee J, et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21248–21255. PubMed PMID: 21081700; PubMed Central PMCID: PMC3003076. DOI:10.1073/pnas.1015855107
   PubMed Web of Science ®Google Scholar
• Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12493–12498. PubMed PMID: 16891410; PubMed Central PMCID: PMC1531646. Doi:10.1073/pnas.0601807103
   PubMed Web of Science ®Google Scholar
• Bergh J, Wiklund T, Erikstein B, et al. Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401. Ann Oncol. 1998 Apr;9(4):403–411. PubMed PMID: 9636831.
   PubMed Web of Science ®Google Scholar
• Rocconi RP, Matthews KS, Kemper MK, et al. Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients. Gynecol Oncol. 2008 Feb;108(2):336–341. PubMed PMID: 18006047. DOI:10.1016/j.ygyno.2007.10.012
   PubMed Web of Science ®Google Scholar
• Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15;21(8):1431–1439. PubMed PMID: 12668651. DOI:10.1200/JCO.2003.09.081
   PubMed Web of Science ®Google Scholar
• Bonilla L, Ben-Aharon I, Vidal L, et al. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst. 2010 Dec 15;102(24):1845–1854. PubMed PMID: 21098761; PubMed Central PMCID: PMC3001963. DOI:10.1093/jnci/djq409
   PubMed Web of Science ®Google Scholar